[Chronic hepatitis C: current therapy and perspectives].
Chronic infection with hepatitis C virus is a "silent epidemic", affecting 170 million people Worldwide. current therapy, that combines pegylated interferon and ribavirin, is of limited efficacy, with percent cure rate. After ten years of relative blockage, new antiviral drugs are announced: viral protease and polymerase inhibitors and drugs that improve several cellular mechanisms of antiviral defence, as ciclophylline blocking agents and nitazoxanide.